Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial

Michiko Asano, Hiroshi Okada,Yohji Itoh,Hajime Hirata,Kensuke Ishikawa,Erika Yoshida,Akiko Matsui,Elizabeth J Kelly,Kathryn Shoemaker,Urban Olsson,Johan Vekemans

International Journal of Infectious Diseases（2022）

引用 16|浏览23

暂无评分

摘要

•All fully vaccinated participants had seroresponses to SARS-CoV-2 spike antigen.•The humoral immune response was comparable with other populations in previous studies.•AZD1222 was well tolerated in Japanese adult participants independent of age.•No apparent differences in safety profile were found compared with results of previous studies.

查看译文

关键词

COVID-19,ChAdOx1 nCoV-19,AZD1222,Japan,Elderly adult,Humoral response

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要